Travera
PrivateLast Round
Series A
Dec 22, 2023
Total Funding Raised
$30.21M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Travera is a biotechnology company that provides a cancer therapy guidance test utilizing single-cell measurement technology to assess tumor cell responses to potential drug treatments in real-time.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Medical Devices
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Travera Comparables
Compare Travera with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| First Ascent Biomedical | 89% | |
| SageMedic Corp. | 84% | |
| Eutropics Pharmaceuticals | 84% |
Travera Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 22, 2023 | ||||
| Accelerator | Jun 6, 2023 | ||||
| Series A Extension | Jul 15, 2021 | ||||
| Grant | Sep 15, 2020 | ||||
| Grant | Jun 1, 2019 | ||||
Grant | Feb 1, 2019 |
Key People
Founding team and executive leadership
Travera Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| Horizons Ventures | Series A, Series A Extension |
| MAS Capital | Series A, Series A Extension |
| MedTech Innovator | Accelerator |
| Khosla Ventures | Series A, Series A Extension |
| National Science Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 121% MoM, from 2.2K to 5K.
- Jul 26, 2026
Monthly visitors increased 58% MoM.
Travera Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Travera's valuation, stock price, and market status.
Is Travera a public or private company?
Travera is a private company.
What is the current stock price of Travera?
Travera is a private company with no public stock price. No recent secondary market data is available.
How much is Travera worth (valuation)?
Valuation information for Travera is not publicly available.
Can I buy Travera stock?
Travera shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Travera's last funding round?
Travera's most recent funding round was Series A on December 22, 2023.
Who are the main investors in Travera?
Key investors in Travera include National Cancer Institute, Khosla Ventures, National Science Foundation.
Will Travera IPO soon?
No public IPO plans have been announced for Travera.
How can I track Travera secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Travera's secondary market activity and sign up for updates.